Has results × Carcinoma, Transitional Cell × Gastrointestinal × Clear all Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
Phase 1/2 Completed
145 enrolled 47 charts
Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies
Phase 1/2 Completed
40 enrolled 11 charts
Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers
Phase 1/2 Completed
34 enrolled 14 charts
A First-in-human Study to Evaluate the Safety and Tolerability of AZD8853 in Participants With Selected Advanced/Metastatic Solid Tumours
Phase 1/2 Terminated
17 enrolled 20 charts
A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer
Phase 1 Completed
175 enrolled 23 charts
Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid Tumors
Phase 1 Terminated
37 enrolled 32 charts
A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors
Phase 1/2 Completed
109 enrolled 25 charts
A Study to Evaluate ONM-100, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer
Phase 2 Completed
30 enrolled 20 charts
PIVOT-02
Phase 1/2 Completed
557 enrolled 22 charts
Arginase-1 Peptide Vaccine in Patients With Metastatic Solid Tumors
Phase 1 Completed
13 enrolled 10 charts
A Phase 1 Study of Mixed Bacteria Vaccine (MBV) in Patients With Tumors Expressing NY-ESO-1 Antigen
Phase 1 Completed
17 enrolled 14 charts
A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies
Phase 1/2 Completed
52 enrolled 25 charts
INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies
Phase 1/2 Terminated
10 enrolled 14 charts
A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat, With or Without Pembrolizumab, in Advanced Solid Tumors
Phase 1/2 Terminated
5 enrolled 4 charts